Previous 10 | Next 10 |
DexCom ( NASDAQ: DXCM ) added ~7% on Thursday after the Centers for Medicare and Medicaid Services (CMS) updated its policy on continuous glucose monitors to expand coverage for a broader group of diabetes patients. The change, expected to take effect in April, is a “welcom...
Summary Remarkable top-line growth coupled with pump shipments. Higher average sale price illustrating improved unit economics for the year. Valuations unsupportive, profitability also a headwind for growth in bottom-line fundamentals. Net-net, rate hold. Investment Su...
Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) enjoy symbiotic relationships with Apple (NASDAQ: AAPL) . The two companies' popular continuous glucose monitoring (CGM) devices used by many patients with diabetes connect to iPhones and Apple Watches. Patients can e...
--News Direct-- Dexcom and Dario think alike when it comes to the elements of an effective solution: user engagement, health outcomes, and return on investment. Diabetics are likely to have more than one chronic condition, Dario’s engaging and highly rated multi-chron...
Summary This is not an immediate call to start buying technology willy nilly. Or is this a tech only announcement. I'm merely projecting that selling pressure will likely reach a crescendo once the Fed raises rates again. Put together a shopping list. You have time to understand the...
Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Small Cap Fund (the “Fund”) was up 4.24% (Institutional Shares) in the fourth quarter of 2022. ...
Americans are getting heavier and have been for a while. According to the Centers for Disease Control and Prevention, U.S. obesity prevalence has increased since 1999, from 30.5% to 41.9%, with severe obesity growing from 4.7% to 9.2%. With all that extra weight comes an increased likelihood ...
Summary Apple continues working on turning the Apple Watch into a medical device. The tech giant has made progress on a glucose monitoring system with the signs the concept works, but the company needs to scale the product into a wearable form factor. The stock is already priced for...
Portfolio includes Dexcom G7, Dexcom ONE and Dexcom G6 and offers the most powerful, easy to use, connected and covered CGM options for people living with diabetes around the world. The portfolio is built on the unparalleled accuracy of Dexcom CGM, 1 supported by more peer reviewed re...
Summary Except for "Jobs", economic data dictates the economy is in a state of "contraction" while Inflation remains "sticky". The recent rally is focused on the notion of a soft landing and the impact the China re-opening will have on the global scene. There is nothing in this econ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-04 10:00:00 ET Growth-oriented investors have experienced a bit of a roller-coaster ride over the past few years. Many companies in the "growth stock" category were struggling just two years ago, but in the bull market we are now experiencing, they're delivering very different resul...
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the...